title: A phase II trial of interleukin-2 and interferon-alpha in the treatment of metastatic colorectal carcinoma.
abstract: A total of 29 patients with stage IV colorectal cancer were entered into a phase II trial of bolus interleukin-2 (IL-2) and interferon-alpha (IFN alpha) (3 x 10(6) U/m2 of each cytokine given i.v. q8h x 15 doses and repeated in 2 weeks). Immunologic parameters measured on isolated peripheral blood lymphocytes revealed increased activated T cells with upregulated natural killer and lymphokine-activated killer activity. Among 24 evaluable patients, there were 4 partial responses (17%) of short duration ( < or = 6 months). Three of the responding patients had been refractory to prior chemotherapy. Overall median survival in the 24 evaluable patients was 18.5 months. Therapy necessitated an inpatient setting, with the most common toxicities being hypotension, hepatic insufficiency, fever, hypocalcemia, nausea/vomiting, and renal insufficiency. There were two treatment-related deaths. Because neither IL-2 nor IFN alpha alone has significant activity against colorectal cancer, the responses observed in this study suggest a potential synergistic effect between the two cytokines. However, the toxicity and short duration of response without survival benefit do not support the routine use of this regimen as a therapeutic modality for this tumor histology.
authors.affiliation: Division of Surgical Oncology, University of Michigan, Ann Arbor 48109, USA.
authors.forename: A E
authors.initials: AE
authors.lastname: Chang
authors.forename: M J
authors.initials: MJ
authors.lastname: Cameron
authors.forename: V K
authors.initials: VK
authors.lastname: Sondak
authors.forename: J D
authors.initials: JD
authors.lastname: Geiger
authors.forename: D L
authors.initials: DL
authors.lastname: Vander Woude
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000556:secondary* / Q000628:therapy*; D015179:Colorectal Neoplasms / Q000628:therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D016233:Immunotherapy, Active; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged
chemical_list: D016898:Interferon-alpha; D007376:Interleukin-2